Bellinger Andrew 4
4 · Verve Therapeutics, Inc. · Filed Feb 16, 2023
Insider Transaction Report
Form 4
Bellinger Andrew
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2023-02-14+182,800→ 182,800 totalExercise: $21.76Exp: 2033-02-13→ Common Stock (182,800 underlying)
Footnotes (1)
- [F1]The option was granted on February 14, 2023. 25% of the shares underlying the option will vest on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027.